Academic literature on the topic 'French administrative healthcare database (SNDS)'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'French administrative healthcare database (SNDS).'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "French administrative healthcare database (SNDS)"
1
Gabet, Amélie, Valérie Olié, and Yannick Béjot. "Stroke Patients with Atrial Fibrillation Treated with Oral Anticoagulants: Comparison of the Population-Based Stroke Registry of Dijon and the French National Health Databases." Neuroepidemiology 54, no. 6 (2020): 506–12. http://dx.doi.org/10.1159/000511206.
Full textAbstract:
<b><i>Introduction:</i></b> The objective of this study was to evaluate the complementarity of the French national health database (<i>Système national des données de Santé</i>, SNDS) and the Dijon Stroke Registry for the epidemiology of stroke patients with anticoagulated atrial fibrillation (AF). <b><i>Methods:</i></b> The SNDS collects healthcare prescriptions and procedures reimbursed by the French national health insurance for almost all of the 66 million individuals living in France. A previously published algorithm was used to identify AF newly treated with oral anticoagulants. The Dijon Stroke Registry is a population-based study covering the residents of the city of Dijon since 1985 and records all stroke cases of the area. We compared the proportions of stroke patients with anticoagulated AF in the city of Dijon identified in SNDS databases to those registered in the Dijon Stroke Registry. <b><i>Results:</i></b> For the period 2013–2017 in the city of Dijon, 1,146 strokes were identified in the SNDS and 1,188 in the registry. The proportion of strokes with anticoagulated AF was 13.4% in the SNDS and 20.3% in the Dijon Stroke Registry. Very similar characteristics were found between patients identified through the 2 databases. The overall prevalence of AF in stroke patients could be estimated only in the Dijon stroke registry and was 30.4% for the study period. <b><i>Discussion/Conclusion:</i></b> If administrative health databases can be a useful tool to study the epidemiology of anticoagulated AF in stroke patients, population-based stroke registries as the Dijon Stroke Registry remain essential to fully study the epidemiology of strokes with anticoagulated AF.
2
Pol, Stanislas, Ingrid Rodriguez, Olivier Lada, Fayssoil fouad, Magali Lemaitre, and Françoise Roudot-Thoraval. "Patients treated for hepatitis C: an observational study with the French administrative healthcare database (SNDS)." Journal of Hepatology 73 (August 2020): S613. http://dx.doi.org/10.1016/s0168-8278(20)31693-7.
Full text
3
Meaume, Sylvie, Patricia Senet, Benoît Thomé, Victor-Alexandre Aragno, Bohbot Serge, Sophie Fortin, Isabelle Boucley, Ulrique Michon-Pasturel, and Hester Colboc. "Impact of primary dressings on healing of venous leg ulcers: a French cohort study from the healthcare insurance database." Journal of Wound Care 33, no. 9 (September 2, 2024): 678–86. http://dx.doi.org/10.12968/jowc.2024.0189.
Full textAbstract:
Objective: Multicomponent bandages (MCBs) are recommended by the French Authority for Health (Haute Autorité de Santé) as first-line treatment for venous leg ulcers (VLUs). A first analysis of the data collected from the French administrative healthcare database (Système National des Données de Santé (SNDS)) on 25,255 patients with a VLU supported superiority of MCBs versus short stretch bandages when considering the healing outcomes and costs associated with closure of these wounds. The aim of this study was to assess how beneficial the primary dressing (technology lipido-colloid nano-oligosaccharide factor (TLC NOSF) or control dressing group (CDG)) could be, when used in combination with MCBs in the treatment of VLUs. Method: Data from the SNDS were collected for patients meeting the following inclusion criteria: treatment for a VLU with MCBs and with the same dressing type (TLC-NOSF or CDG) during the whole treatment period. Healing outcomes were documented on the global cohorts and propensity score-matched cohorts. The mean healthcare cost and the ecological impact were calculated for those patients healed within the study period. Results: In total, 12,507 patients met the criteria for treatment with both MCBs and TLC-NOSF dressings (n=1134) versus MCBs and CDG (n=11,373); with 1134 and 2268 patients per group following propensity score matching. Healing outcomes were favourable for the TLC-NOSF group in the global cohort and were enhanced in the propensity score-matched cohorts. At every point of the analysis, the adjusted healing rates were significantly higher in the TLC-NOSF group than in the CDG group (p<0.001). In the propensity score-matched cohorts (n=3402), the healing rate at three months was 52% in the TLC-NOSF group versus 37% in the CDG group (p<0.001). The median healing time was 87 days versus 125.5 days in the TLC-NOSF and CDG groups, respectively (p<0.0001). TLC-NOSF dressings significantly reduced the average treatment cost per healed ulcer (€2099) by 23.7% compared with dressings without TLC-NOSF (€2751) (p<0.001), as well as the resources used. Conclusion: This SNDS analysis confirms, in the largest real-life study performed in VLU management, the superiority of the TLC-NOSF dressings versus those not impregnated with the NOSF compound. Better clinical outcomes associated with cost savings and a positive ecological impact support the combination of MCBs and TLC-NOSF dressings and should be considered as an optimal standard of care for the global management of VLUs. These outcomes reinforce the current positions of the international guidelines on the use of NOSF impregnated dressings (UrgoStart range; Laboratoires Urgo, France) in this pathology.
4
Lartigau, Marion, Martine Barateau, Mathieu Rosé, Nicoleta Petricã, and Nathalie Salles. "Pressure ulcer prevention devices in the management of older patients at risk after hospital discharge: an SNDS study." Journal of Wound Care 32, Sup9a (September 1, 2023): clxxi—clxxx. http://dx.doi.org/10.12968/jowc.2023.32.sup9a.clxxi.
Full textAbstract:
Objective: Our aim was to measure the effectiveness of home healthcare pressure ulcer (PU) prevention devices (PUPDs) for at-risk patients after hospital discharge in France. Method: We conducted a retrospective analysis of PU-associated hospitalisations based on the French medico-administrative database (Système National des Données de Santé, SNDS), which covers the entire French population. All adults >70 years of age, hospitalised from 1 July to 31 December 2015, and equipped with a medical bed at home, were included. Follow-up was for a maximum of 18 months. Propensity score matching allowed the comparison of PUPD equipped and non-equipped groups (No-PUPD), considering sociodemographic characteristics and other factors. Results: The study included 43,078 patients. Of this population, 54% were PUPD patients and 46% No-PUPD. After matching, PUPD patients had significantly fewer PUs than No-PUPD patients (5.5% versus 8.9%, respectively; p<0.001). The adoption of PUPD reduced by 39% the risk of a PU in hospital. Patients equipped within the first 30 days at home after hospitalisation had fewer PUs than those equipped later (4.8% versus 5.9%, respectively). The estimated PUPD use costs represented 1% of total healthcare expenditure per patient during the study period. Conclusion: The study results demonstrated the effectiveness of the adoption of mattress toppers or prevention mattresses in reducing PU occurrence in patients aged >70 years of age. A short delay in PUPD delivery appeared to have a real impact in the medical setting. Future research on a larger population might provide more evidence on the appropriate support and timeframe to choose based on risk assessment.
5
Juge, P. A., L. Wemeau Stervinou, S. Ottaviani, G. Desjeux, J. Zhuo, B. Bregman, V. Vannier-Moreau, R. M. Flipo, B. Crestani, and P. Dieudé. "OP0099 EPIDEMIOLOGY AND MORTALITY OF RA-ASSOCIATED INTERSTITIAL LUNG DISEASE: DATA FROM A FRENCH ADMINISTRATIVE HEALTHCARE DATABASE." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 54.2–55. http://dx.doi.org/10.1136/annrheumdis-2021-eular.871.
Full textAbstract:
Background:Interstitial lung disease (ILD) is a common extra-articular manifestation of RA and is associated with increased morbidity and mortality.1-3 Studies have shown variability in the prevalence and mortality rate of patients with RA-associated ILD (RA-ILD).4 Further studies are needed to better characterise the epidemiology of RA-ILD.Objectives:To estimate the prevalence and incidence of clinical RA-ILD in France and to compare mortality rates between patients with RA-ILD and patients with RA without clinical ILD (RA-noILD).Methods:A historical cohort study was conducted using data from the French national claims database (SNDS) between 1 January 2013 and 31 December 2018. Adults with an RA diagnosis (International Classification of Diseases, Tenth revision [ICD-10] codes M05, M06.0, M06.8 and M06.9) and ≥2 distinct dates of DMARD delivery were included. Onset of RA was defined as the first date of occurrence between RA codes and the first known DMARD reimbursement. ILD diagnosis was defined as having ICD-10 code J84 and ≥1 computed tomography scan after, but within 1 year of, the first date of ILD occurrence. All patients had ≥6 months’ reimbursement after RA-ILD onset. The prevalence and incidence (2014–2018) of RA-ILD were estimated. The mortality rate was calculated, comparing patients with RA-ILD and patients with RA-noILD, matched 1:1 for age, sex, age at RA-ILD onset, duration of RA and presence of diabetes, arterial disease, dyslipidaemia and cardiac disease. Mortality was compared between patients with RA with and without clinical ILD in the matched population using Cox proportional hazards regression.Results:The prevalence of RA-ILD was 6.52 per 100,000 inhabitants (incidence=1.04 per 100,000 person-years). Of the 173,138 patients with RA included in the overall population, 4330 (2.5%) had clinical ILD. Patients with RA-ILD were older at RA diagnosis (mean [SD] age: 63.3 [13.7] vs 56.9 [15.2] years) and were more likely to be male (39.8% vs 27.0%) compared with patients with RA-noILD. Patients with RA-ILD were more likely to have cardiac disease (84.9% vs 63.1%), arterial disease (38.0% vs 19.3%), diabetes (21.4% vs 12.5%) and dyslipidaemia (44.7% vs 32.9%) compared with those with RA-noILD. The mortality rate in patients with clinical RA-ILD was 1.71 per 100,000 inhabitants. The mortality rate increased according to age (0.28 per 100,000 inhabitants for patients aged <65 years, 4.60 per 100,000 inhabitants for patients aged 65–74 years and 11.4 per 100,000 inhabitants for patients aged ≥75 years). After matching, the adjusted mortality risk was three times higher (HR [95% CI]: 3.1 [3.1, 3.9]) in patients with RA-ILD than in those with RA-noILD (Figure 1).Conclusion:This is the largest epidemiological study of RA-ILD in France. The prevalence of clinical RA-ILD in this population was towards the lower end of previous estimates (1–58%),3 possibly due to under-reporting of claims data. However, the occurrence of clinical ILD was associated with a strong increase in mortality compared with patients with RA-noILD.References:[1]Bodolay E, et al. Rheumatology (Oxford) 2005;44:656–661.[2]Duarte AC, et al. Rheumatology (Oxford) 2019;58:2031–2038.[3]Hyldgaard C, et al. Ann Rheum Dis 2017;76:1700–1706.[4]Spagnolo P, et al. Arthritis Rheumatol 2018;70:1544–1554.Acknowledgements:This study was funded by Bristol Myers Squibb. Claire Line, PhD of Caudex provided medical writing support, funded by Bristol Myers Squibb.Disclosure of Interests:Pierre-Antoine Juge Consultant of: Bristol Myers Squibb, Lidwine Wemeau Stervinou Consultant of: Boehringer Ingelheim, Bristol Myers Squibb, Roche, Sanofi, Sebastien Ottaviani Consultant of: AbbVie, Bristol Myers Squibb, Lilly, Merck Sharp & Dohme, Novartis, Roche-Chugai, SOBI, UCB, Guillaume Desjeux: None declared, Joe Zhuo Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Bruno Bregman Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Virginie Vannier-Moreau Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Rene-Marc Flipo Speakers bureau: AbbVie, Bristol Myers Squibb, Janssen, Lilly, Medac, Merck Sharp & Dohme, Novartis, Pfizer, Roche-Chugai, Grant/research support from: Amgen, Janssen, Novartis, Pfizer, Bruno Crestani: None declared, Philippe Dieudé Consultant of: Boehringer Ingelheim, Bristol Myers Squibb, Chugaï, Lilly, Medac, Novartis, Pfizer, Sanofi, Grant/research support from: Bristol Myers Squibb, GlaxoSmithKline, Pfizer
6
Meaume, Sylvie, Patricia Senet, Benoît Thomé, Victor-Alexandre Aragno, Serge Bohbot, Sophie Fortin, Isabelle Boucley, Ulrique Michon-Pasturel, and Hester Colboc. "Aetiological treatment of venous leg ulcers with compression therapy: real-life outcomes with two different procedures." Journal of Wound Care 32, no. 10 (October 2, 2023): 615–23. http://dx.doi.org/10.12968/jowc.2023.32.10.615.
Full textAbstract:
Objective: To evaluate the healing outcomes and costs associated with the aetiological management of venous leg ulcers (VLUs) treated with recommended multicomponent bandages (MCBs) and short-stretch bandages (SSBs). Method: This observational study is a retrospective comparative study (Level 2b), based on the French administrative healthcare database (Système National des Données de Santé, SNDS). It includes patients treated from onset with reimbursed MCBs and SSBs for a VLU episode, between July 2018 and September 2020. Although other compression systems, such as long-stretch bandages, are commonly used for the treatment of VLUs, they are not recommended by health authorities in France and thus, were not considered for this study. A binomial regression model was performed to estimate the adjusted relative risk of wound closure rates at three months for each group, based on potential confounding factors including, notably, age, sex, key comorbidities, and wound dressing size. The mean healthcare cost was calculated for patients whose VLUs healed within the study period. Results: The reimbursement data (including prescribed compression systems and nursing care) of the 25,255 selected patients were analysed in the study. There were no significant differences between the MCBs and SSBs groups when considering patient characteristics. The healing rates after three months' treatment, were 42% and 35% (p<0.001) in the MCBs and SSBs groups, respectively. When adjusting the statistical model, the chance of healing at three months was still 12% higher with MCBs compared with SSBs (p<0.0001). The median healing time was estimated at 115 (interquartile range (IQR): 60–253) days in the MCB group versus 137 (IQR: 68–300) days in the SSBs group. The average treatment cost per patient with a healed ulcer was €2875±3647 in the MCB group and €3580±5575) in the SSBs group (p=0.0179), due to lower hospital stay and nursing costs in the MCB group. Differences in wound characteristics between the two groups cannot be totally excluded, due to the limited content of the database in terms of clinical data, but should have been addressed, to some extent, through the study selection criteria and the chosen regression model. Conclusion: In this study, this SNDS analysis seemed to confirm that the healing outcomes achieved in real-life with MCBs were in line with those reported in clinical trials, and superior to SSBs, which reinforces the current position from the guidelines.
7
Bastard, Léa, Pascal Claudepierre, Laetitia Penso, Emilie Sbidian, and Laura Pina Vegas. "Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS)." RMD Open 10, no. 1 (March 2024): e003865. http://dx.doi.org/10.1136/rmdopen-2023-003865.
Full textAbstract:
ObjectiveTo assess the risk of serious infection associated with different targeted therapies for psoriatic arthritis (PsA) in real-world settings.MethodsThis nationwide cohort study used the administrative healthcare database of the French health insurance scheme linked to the hospital discharge database to identify all adults with PsA who were new users of targeted therapies (adalimumab, etanercept, golimumab, certolizumab pegol, infliximab, secukinumab, ixekizumab, ustekinumab, and tofacitinib) from 1 January 2015 to 30 June 2021. The primary outcome was a serious infection (ie, requiring hospitalisation), in a time-to-event analysis using propensity score-weighted Cox models, with adalimumab as the comparator, estimating weighted HRs (wHRs) and their 95% CIs.ResultsA total of 12 071 patients were included (mean age 48.7±12.7 years; 6965 (57.7%) women). We identified 367 serious infections (3.0% of patients), with a crude incidence rate of 17.0 per 1000 person-years (95% CI, 15.2 to 18.7). After inverse propensity score weighting and adjustment for time-dependent covariates and calendar year, risk of serious infection was significantly lower for new users of etanercept (wHR 0.72; 95% CI, 0.53 to 0.97) or ustekinumab (wHR, 0.57; 95% CI, 0.35 to 0.93) than adalimumab new users. This risk was not statistically modified with the other targeted therapies.ConclusionsThe incidence of serious infection was low for PsA patients who were new users of targeted therapies in real-world settings. Relative to adalimumab new users, this risk was lower among new users of etanercept and ustekinumab and unmodified for the other molecules.
8
Pol, Stanislas, Fayssoil Fouad, Magali Lemaitre, Ingrid Rodriguez, Olivier Lada, Pascaline Rabiega, Elias Benabadji, and Françoise Roudot-Thoraval. "Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS)." Lancet Regional Health - Europe 13 (February 2022): 100281. http://dx.doi.org/10.1016/j.lanepe.2021.100281.
Full text
9
Pina Vegas, Laura, Léa Hoisnard, Léa Bastard, Emilie Sbidian, and Pascal Claudepierre. "Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS)." RMD Open 8, no. 2 (December 2022): e002681. http://dx.doi.org/10.1136/rmdopen-2022-002681.
Full textAbstract:
IntroductionTumour necrosis factor inhibitor (TNFi) agents are most often the first-choice biological treatment for patients with psoriatic arthritis (PsA). When their discontinuation is needed, a switch to another TNFi or to another therapeutic class may be considered. However, data supporting one approach over another are lacking.ObjectiveTo compare the long-term persistence of classes of biologics in PsA patients with prior TNFi exposure.MethodsThis nationwide cohort study involved the administrative healthcare database of the French health insurance scheme linked to the hospital discharge database. We included all adults with PsA starting a second-line biological after discontinuing a TNFi during 2015–2020. Persistence was defined as the time from biological initiation to discontinuation and was estimated by the Kaplan-Meier method. Comparison of persistence by biological class was performed with Poisson regression models with time divided into 6-month intervals.ResultsWe included 2975 patients: 1580 (53%) initiating a second TNFi, 426 (14%) an interleukin 12/23 inhibitor (IL-12/23i) and 969 (33%) an IL-17 inhibitor (IL-17i). Overall, 1-year and 3-year persistence rates were 42% and 17%, respectively. After adjustment, persistence was associated with treatment with an IL-17i (adjusted relative risk (RRa) 0.79, 95% CI 0.71 to 0.87) or IL-12/23i (RRa0.69, 95% CI 0.61 to 0.79) vs a TNFi, with no significant difference between IL-12/23 and IL-17 inhibitors (RRa0.88, 95% CI 0.76 to 1.02).ConclusionsOverall, this real-life study shows low persistence for all biologics at 3 years in PsA patients previously exposed to a TNFi. However, persistence was higher with an IL-17i or IL-12/23i than a TNFi.
10
Pina Vegas, Laura, Laetitia Penso, Emilie Sbidian, and Pascal Claudepierre. "Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS)." RMD Open 9, no. 4 (December 2023): e003570. http://dx.doi.org/10.1136/rmdopen-2023-003570.
Full textAbstract:
BackgroundSex differences in phenotype presentation, disease trajectory and treatment response in psoriatic arthritis (PsA) have been reported. Nevertheless, whether classes of targeted therapies differentially affect men and women with PsA remains unclear.ObjectivesTo assess the effect of sex on the long-term persistence of each class of targeted therapies in PsA.MethodsThis nationwide cohort study involved the administrative healthcare database of the French health insurance scheme linked to the hospital discharge database. We included all adults with PsA who were new users of targeted therapies (not in the year before the index date) during 2015–2021 and studied all treatment lines during the study period. Persistence was defined as the time from treatment initiation to discontinuation and was estimated by the Kaplan-Meier method. Comparison of persistence by sex involved multivariate frailty models with conventional synthetic disease-modifying antirheumatic drugs and prednisone as time-dependant variables.ResultsWe included 14 778 patients with PsA who were new users of targeted therapies: 8475 (57%) women (mean age 50±13 years; 15 831 lines), 6303 (43%) men (mean age 51±13 years; 10 488 lines). Overall, 1-year persistence was 52% for women and 62% for men and at 3 years it was 27% and 39%, respectively. After adjustments, persistence was lower for women than men for inhibitors of tumour necrosis factor (TNFi) (adjusted HR (HRa) 1.4, 99% CI 1.3 to 1.5) and interleukin 17 inhibitor (IL17i) (HRa1.2, 99% CI 1.1 to 1.3) but not IL12/23i (HRa1.1, 99% CI 0.9 to 1.3), IL23i (HRa1.1, 99% CI 0.7 to 1.5) or Janus kinase inhibitor (JAKi) (HRa1.2, 99% CI 0.9 to 1.6).ConclusionThe treatment persistence was lower for women than men for TNFi and IL17i but not for IL12/23i, IL23i or JAKi.
Dissertations / Theses on the topic "French administrative healthcare database (SNDS)"
1
Duong, Chi-Hong. "Approches statistiques en pharmacoépidémiologie pour la prise en compte des facteurs de confusion indirectement mesurés dans les bases de données médico-administratives : Application aux médicaments pris au cours de la grossesse." Electronic Thesis or Diss., université Paris-Saclay, 2024. http://www.theses.fr/2024UPASR028.
Full textAbstract:
Les bases de données médico-administratives sont de plus en plus utilisées en pharmacoépidémiologie. Néanmoins, l'existence de facteurs de confusion (FDC) non mesurés et non pris en compte peut biaiser les analyses. Dans ce travail, nous explorons l'intérêt d'exploiter la richesse des données avec la sélection à large échelle d'un grand nombre de covariables mesurées corrélées avec d'éventuels facteurs manquants pour les ajuster indirectement. Ce concept est à la base du score de propension en grande dimension (hdPS), et nous appliquons la même démarche à la G-computation (GC) et l'estimation Ciblée par Maximum de Vraisemblance (TMLE). Bien que ces méthodes aient été évaluées dans certaines études de simulation, leurs performances sur de grandes bases de données réelles restent peu étudiées. Cette thèse vise à évaluer leurs contributions à l'atténuation de l'effet de FDC directement ou indirectement mesurés dans le système national des données de santé (SNDS) pour des études de pharmacoépidémiologie chez la femme enceinte. Dans le chapitre 2, nous avons utilisé un ensemble de médicaments de référence en lien avec la prématurité pour comparer les performances des trois méthodes. Toutes ont diminué le biais de confusion, la GC donnant les meilleures performances. Dans le chapitre 3, nous avons réalisé une analyse par hdPS dans un contexte de modélisation plus complexe pour étudier le lien controversé entre les anti-inflammatoires non stéroïdiens (AINS) et la fausse couche spontanée (FCS). Nous avons implémenté un modèle de Cox avec variable dépendant du temps et l'approche “lag-time” visant à corriger d'autres biais (biais de temps immortel et biais protopathique). Nous avons comparé des analyses basées sur les facteurs d'ajustement choisis selon la littérature actuelle ou avec le hdPS. Dans ces deux types d'analyse, les AINS étaient associés à un surrisque de FCS, les différences observées dans les risques estimés pouvant s'expliquer en partie par la différence entre les estimands théoriques ciblés par les approches. Nos travaux permettent de confirmer la contribution des méthodes statistiques à atténuer le biais de confusion. Ils soulignent aussi des difficultés majeures rencontrées lors de leur application en pratique en lien avec la complexité de la modélisation et du plan d'étude, ainsi qu'avec leur coût computationnelHealthcare administrative databases are increasingly used in pharmacoepidemiology. However, the existence of unmeasured and uncontrolled confounders can bias analyses. In this work, we explore the value of leveraging the richness of data through large-scale selection of a large number of measured covariates correlated with unmeasured confounders to indirectly adjust for them. This concept is the cornerstone of the High-dimensional propensity score (hdPS), and we apply the same approach to G-computation (GC) and Targeted Maximum Likelihood Estimation (TMLE). Although these methods have been evaluated in some simulation studies, their performance on large real-world databases remains underexplored. This thesis aims to assess their contributions to mitigating the effect of directly or indirectly measured confounders in the French administrative health care database (SNDS) for pharmacoepidemiological studies in pregnant women. In Chapter 2, we used a set of reference drugs related to prematurity to compare the performance of the three methods. All reduced confounding bias, with GC showing the best performance. In Chapter 3, we conducted an hdPS analysis in a more complex modeling setting to investigate the controversial association between non-steroidal anti-inflammatory drugs (NSAIDs) and miscarriage. We implemented a Cox model with time-dependent variables and the “lag-time” approach to address other biases (immortal time bias and protopathic bias). We compared analyses adjusted for factors chosen according to the current literature with those chosen by the hdPS algorithm. In both types of analysis, NSAIDs were associated with an increased risk of miscarriage, and the observed differences in estimated risks could partly be explained by the difference between the causal estimands targeted by the approaches. Our work confirms the contribution of statistical methods to reducing confounding bias. It also highlights major challenges encountered during their practical application, related to the complexity of modeling and study design, as well as their computational cost
Book chapters on the topic "French administrative healthcare database (SNDS)"
1
Koïvogui, Akoi, Robert Benamouzig, and Catherine Duclos. "Refinement of the Target Population for Colorectal Cancer Screening in France, Inventory as a Prelude to the Use of Medico-Administrative Database." In Caring is Sharing – Exploiting the Value in Data for Health and Innovation. IOS Press, 2023. http://dx.doi.org/10.3233/shti230157.
Full textAbstract:
The study describes the level of improvement in the risk of misclassification that would be achieved by refining the campaign target population using a query in the French medico-administrative database (SNDS). The SNDS’s use requires other new strategies that can minimize the number of people wrongly included in the campaigns, because its accuracy is less than 100%.
Conference papers on the topic "French administrative healthcare database (SNDS)"
1
Pina Vegas, L., S. Iggui, E. Sbidian, and P. Claudepierre. "POS0959 IMPACT OF INITIATION OF TARGETED THERAPY ON THE USE OF ASSOCIATED TREATMENTS AND HEALTHCARE CONSUMPTION IN PSORIATIC ARTHRITIS: A COHORT STUDY OF 9,793 PATIENTS FROM THE FRENCH HEALTH INSURANCE DATABASE (SNDS)." In EULAR 2024 European Congress of Rheumatology, 12-15 June. Vienna, Austria. BMJ Publishing Group Ltd and European League Against Rheumatism, 2024. http://dx.doi.org/10.1136/annrheumdis-2024-eular.928.
Full text